Risk factors in MM: is it time for a revision?

Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.

View the article @ Blood (sign-in may be required)

Get PDF with LibKey